CD8A and glioblastoma: This inhibitory effect was found to be achieved by GBM cell-derived exosomal LGALS9 (lectin, galactoside-binding soluble 9), which targets DCs in CSF and suppresses the antitumor immunity of CD8+ T cells [66].